- Ab01093-1.32 Anti-HER2 [4D5]
- Mouse IgG1-D265A
- Fc Silenced
- In Stock
Recombinant monoclonal antibody to HER2. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 4D5.
UniProt Accession Number of Target Protein: P04626
Alternative Name(s) of Target: CD340; NEU; HER-2; HER-2/neu; ERBB2; MLN 19; NGL; TKR1; erb-b2 receptor tyrosine kinase 2; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2
Immunogen: The original antibody was generated by immunizing BALB/c mice with NIH 3T3/HER2-3400 cells expressing high levels of p185HER2.
Specificity: The original antibody is directed against the extracellular domain of p185HER2. This antibody does not cross-react with the human EGF receptor (HER1).
Application Notes: The antibody immunoprecipitated p185HER2 from NIH3T3 cells. The binding of the antibody to human tumor cell lines was investigated by fluorescence-activated cell sorting. Increased in cellular fluorescence observed with SK-BR-3 breast adenocarcinoma cells and squamous carcinoma cell line A431, where the binding of the antibody correlated with the levels of p185HER2 expressed by these two cell lines. The antibody inhibited cellular proliferation of SK-BR-3 overexpressing p185HER2 by 56%. The antibody significantly affected the growth of the cell lines MDA-MB-361 and MDA-MB-175-VII, which also express high levels of p185HER2. Further, the antibody completely prevented colony formation by these cells in soft agar. Furthermore, resistance to the cytotoxic effect of tumor necrosis factor alpha is significantly reduced in the presence of this antibody (Hudziak et al., 1989; PMID: 2566907). The humanized IgG1 version of the antibody was constructed and it bound the p185HER2 antigen with higher affinity compared to its parent antibody, it had a similar potency in blocking SK-BR-3 cell proliferation and it supported antibody-dependent cellular cytotoxicity against SK-BR-3 cells (Carter et al., 1992; PMID: 1350088). The structure of the humanized Fab and Fv fragments of the antibody were determined (Eigenbrot et al., 1993; PMID: 8095303). The humanized version of the antibody, trastuzumab, was found to inhibit the growth of human cancer cells and tumor xenografts overexpressing HER2 (Albanell et al., 1999; PMID: 12973420). The Fc silent version of the original antibody was used for mouse tumor growth assays (Campbell et al., 2022; PMID: 35108526). The humanized version of the antibody was used for detection of p185HER-2 expressed on SKBR3 or T6-17 cells by flow cytometry. The antibody was used for immunoprecipitation from T6-17 and B104-1-1 cells (Zhang et al., 1999; PMID: 10493889).
Antibody first published in:
Hudziak et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor Mol Cell Biol
. 1989 Mar;9(3):1165-7 PMID:2566907
Note on publication: The paper describes the generation and characterization of the antibody, which is specific for HER2.